Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US Senate clears PEPFAR bill with HIV treatment thresholds

This article was originally published in Scrip

Executive Summary

The US House is expected this week to approve a Senate bill renewing and expanding the President's Emergency Plan for AIDS Relief (PEPFAR) programme. The measure would require more than half of all HIV/AIDS funding be spent on treatment and open an avenue for the PEPFAR programme to purchase antiretrovirals approved by regulators other than the FDA.

You may also be interested in...



Mylan Plans To Compete In US HIV Market With Two Fixed-Dose Combos

Generics firm will launch single-tablet regimens of older HIV drugs not otherwise available as combos in US, with discounted pricing.

Mylan Plans To Compete In US HIV Market With Two Fixed-Dose Combos

Generics firm will launch single-tablet regimens of older HIV drugs not otherwise available as combos in US, with discounted pricing.

COVID-19 Vaccines: Advisory Committee Picks Apart US FDA Guidance On Efficacy Endpoints

FDA's recommendation that COVID-19 vaccine sponsors conduct two months of median follow-up to support an emergency use authorization may not be long enough, some experts say in what can be viewed as validation for agency's position in battle with White House.

Topics

UsernamePublicRestriction

Register

LL1134361

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel